This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignee: Taiho Pharmaceutical Company Limited. Active years: 2017-2018.
Company Filing History:
Years Active: 2017-2018
Title: Innovations by Toshihiro Osada in Cancer Vaccine Development
Introduction
Toshihiro Osada is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of cancer immunotherapy through his innovative peptide compositions. With a total of 2 patents, his work focuses on developing peptide vaccines that can be administered to a diverse range of cancer patients.
Latest Patents
Osada's latest patents include groundbreaking inventions aimed at enhancing cancer treatment. The first patent, titled "Peptide compositions having 4 linked CTL epitopes and uses thereof," provides a cancer antigen peptide that can be administered without the need for HLA typing. This innovation allows for a peptide vaccine that is effective regardless of the HLA types of patients. The peptide is created by linking four CTL epitope peptides derived from tumor antigen molecules known for their capacity to induce CTL responses.
The second patent, "Peptide having 5 linked CTL epitopes," follows a similar concept. It offers a cancer antigen peptide that can also be administered without HLA typing. This peptide is obtained by linking five CTL epitope peptides, further expanding the potential for effective cancer vaccines across various patient demographics.
Career Highlights
Toshihiro Osada is currently associated with Taiho Pharmaceutical Company Limited, where he continues to innovate in the field of cancer treatment. His work is pivotal in developing therapies that can potentially save lives by providing accessible treatment options for cancer patients.
Collaborations
Osada collaborates with esteemed colleagues such as Satoshi Fukaya and Hiroshi Wada. Their combined expertise contributes to the advancement of cancer immunotherapy and the development of effective peptide vaccines.
Conclusion
Toshihiro Osada's contributions to cancer vaccine development through his innovative peptide compositions highlight the importance of research in improving treatment options for cancer patients. His work exemplifies the potential of scientific innovation in addressing critical health challenges.